LegitHealthSAN
Completed
16 enrolled
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Recruiting
200 enrolled
Post-Marketing Surveillance Study of OTEZLA
Completed
1,086 enrolled
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Completed
2,207 enrolled 10 charts
DermaFlow
Recruiting
8,000 enrolled
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
Active not recruiting
2,000 enrolled
QUANTUM
Enrolling by invitation
3,000 enrolled
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting
20,000 enrolled
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Completed
17,667 enrolled
A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis
Completed
103 enrolled 18 charts